Description
Arachidonoyl ethanolamide (AEA; ) was the first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB
1 and CB
2) as Δ
9-
THC . Since that time, a number of related endocannabinoids have been isolated, most notably 2-
arachidonoyl glycerol (2-
AG; ). The phosphate ester of AEA, AEA-
P, has been tested as a water soluble prodrug version of AEA in the treatment of C
6 glioma cells
in vivo. Here it acts with essentially the same potency as AEA. However, when tested for inhibition of AEA binding to isolated rat brain CB
1 receptors, AEA-
P is about 5-
fold less potent as an agonist with a K
i of about 200 nM. The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA). However, the effects of AEA-
P on the various LPA receptors have not been tested.
Uses
Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype)[1][2].
References
[1] M Maccarrone, et al. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem. 2000 Oct 13;275(41):31938-45. DOI:
10.1074/jbc.M005722200[2] S O Jacobsson, et al. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther. 2001 Dec;299(3):951-9. PMID:11714882